Search Results for "Proquad Clinical Trial Phase Dose"
Matching Channels
ATX-MS-1467 for patients with multiple sclerosis (MS)
ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the...
Clinical trials involving new drugs are commonly classified into four phases. Each phase of the drug approval process is treated as a separate clinical trial. The drug-development process will norma...
Kadcyla (ado-trastuzumab emtansine)
Kadcyla™ (ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin® (trastuzumab)...
Matching News
BrainStorm initiates NurOwn Phase IIa dose-escalating trial in ALS
BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the first patient began treatment in the Company's Phase IIa dose...
We describe a dose escalation procedure for a combined phase I/II clinical trial. The procedure is based on a Bayesian model for the joint distribution of the occurrence of a dose limiting event and o...
Tekmira's TKM-PLK1 Is Promising For Solid Tumors
By Grant Zeng: Phase I Data of TKM-PLK1 Are Encouraging On April 9, 2013, Tekmira Pharmaceuticals (TKMR) announced the results of its Phase I clinical trial with TKM-PLK1 at the annual mee...
Arena begins Phase 1 PAH trial of APD811
Arena Pharmaceuticals has commenced patient dosing in a double-blind Phase 1 multiple dose clinical trial of APD811 for pulmonary arterial hypertension (PAH).
Higher-Dose Radiotherapy for Stage III Lung Cancer Patients Results in Inferior Survival
In a recent US randomized phase III clinical trial, high-dose radiotherapy compared with standard-dose radiotherapy with concurrent chemotherapy did not...
Pacira Pharmaceuticals reports results of EXPAREL Phase 2/3 clinical trial for TKA
Pacira Pharmaceuticals, Inc. today announced findings from the completed first part of its Phase 2/3 clinical trial assessing the use and administration of EXPAREL (bupivacaine liposome injectable sus...
Medicago receives Health Canada authorization for phase II trial
Medicago, a biopharmaceutical company focused on developing vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), has received clearance by Health Canada to initiat...
Novartis data at ERS shows efficacy of once-daily COPD portfolio versus comparators
Further data from the Novartis once-daily chronic obstructive pulmonary disease (COPD) clinical trial programs were presented at the European Respiratory Society (ERS) Congress. Overall, Novartis pres...
Matching PubMed Articles
Vaccination against measles, mumps, rubella and varicella (MMRV) is currently recommended in developed countries for infants from 12 months of age. However, measles vaccination at 9 months of age is r...
Adaptive dose insertion in early phase clinical trials.
BACKGROUND: and PURPOSE: We propose to adaptively insert new doses during the course of a dose-finding trial when none of the prespecified doses in the trial are acceptable, for example, have tolerabl...
BACKGROUND: The purpose of this phase I trial of S-1 chemotherapy in combination with pelvic radiotherapy for locally recurrent rectal cancer was to determine the maximum tolerat...
Randomized Phase II Trial Designs With Biomarkers.
Efficient development of targeted therapies that may only benefit a fraction of patients requires clinical trial designs that use biomarkers to identify sensitive subpopulations. Various randomized ph...
Linezolid is an important therapeutic option for infections from multi-drug resistant Gram-positive pathogens. However, prolonged linezolid treatment (>14 days) is considered to increase the risk of h...
